Literature DB >> 9258955

Neutral and acid mucins and eosinophil and argyrophil crystalloids in carcinoma and atypical adenomatous hyperplasia of the prostate.

S Luna-Moré1, P Florez, A Ayala, F Diaz, A Santos.   

Abstract

Neutral and acid mucins and eosinophil and argyrophil crystalloids were studied in the glandular intraluminal contents of 130 prostatic carcinomas (PCa) and 22 atypical adenomatous hyperplasias (AAH). Specimens were studied in the usual extension for diagnostic purposes and considered positive when minimal amounts of mucin or any crystalloid were present. Some amount of altered secretion was seen in 110 PCa (84.6%) and in 17 AAH (77.3%); the similarity of the figures speaks for the close relationship of these lesions. The relative incidences in PCa/AAH were 61.5%/77.3% for neutral mucin, 80%/54.5% for acid mucin (p < 0.01), 25.4%/50% for eosinophil crystalloids (p < 0.02), 44.6%/9.1% for argyrophil crystalloids (p < 0.01) and 57%/36% for a compound secretion. The incidence of eosinophil crystalloids was greater in AAH and inversely proportional to the Gleason grade in PCa. The incidence of acid mucins and argyrophil crystalloids was higher in PCa and directly proportional to the tumour grade in all but the poorly differentiated ones. It is therefore suggested that AAH positive for acid mucins or argyrophil crystalloids be classified in the high grade AAH group.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9258955     DOI: 10.1016/S0344-0338(97)80006-4

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  11 in total

1.  GM-CSF production by glioblastoma cells has a functional role in eosinophil survival, activation, and growth factor production for enhanced tumor cell proliferation.

Authors:  Colleen S Curran; Michael D Evans; Paul J Bertics
Journal:  J Immunol       Date:  2011-06-24       Impact factor: 5.422

2.  Blood Eosinophils Are Associated with Efficacy of Targeted Therapy in Patients with Advanced Melanoma.

Authors:  Simone Wendlinger; Jonas Wohlfarth; Sophia Kreft; Claudia Siedel; Teresa Kilian; Ulrich Dischinger; Markus V Heppt; Kilian Wistuba-Hamprecht; Friedegund Meier; Matthias Goebeler; Dirk Schadendorf; Anja Gesierich; Corinna Kosnopfel; Bastian Schilling
Journal:  Cancers (Basel)       Date:  2022-05-04       Impact factor: 6.575

Review 3.  Myeloid Cells as Targets for Therapy in Solid Tumors.

Authors:  Tiziana Cotechini; Terry R Medler; Lisa M Coussens
Journal:  Cancer J       Date:  2015 Jul-Aug       Impact factor: 3.360

4.  Incidental prostate ¹⁸F-FDG uptake without calcification indicates the possibility of prostate cancer.

Authors:  Hiroko Seino; Shuichi Ono; Hiroyuki Miura; Satoko Morohashi; Yunyan Wu; Fumiyasu Tsushima; Yoshihiro Takai; Hiroshi Kijima
Journal:  Oncol Rep       Date:  2014-02-04       Impact factor: 3.906

Review 5.  From Allergy to Cancer-Clinical Usefulness of Eotaxins.

Authors:  Monika Zajkowska; Barbara Mroczko
Journal:  Cancers (Basel)       Date:  2021-01-03       Impact factor: 6.639

6.  The role of innate lymphoid cells in selected disease states - cancer formation, metabolic disorder and inflammation.

Authors:  Agata Poniewierska-Baran; Beata Tokarz-Deptuła; Wiesław Deptuła
Journal:  Arch Med Sci       Date:  2019-11-18       Impact factor: 3.318

Review 7.  Potential impact of invasive surgical procedures on primary tumor growth and metastasis.

Authors:  Maria Alieva; Jacco van Rheenen; Marike L D Broekman
Journal:  Clin Exp Metastasis       Date:  2018-05-04       Impact factor: 5.150

8.  Eosinophil prognostic scores for patients with head and neck squamous cell carcinoma treated with nivolumab.

Authors:  Daisuke Nishikawa; Hidenori Suzuki; Shintaro Beppu; Hoshino Terada; Michi Sawabe; Shigenori Kadowaki; Michihiko Sone; Nobuhiro Hanai
Journal:  Cancer Sci       Date:  2020-11-04       Impact factor: 6.518

Review 9.  Eotaxins and Their Receptor in Colorectal Cancer-A Literature Review.

Authors:  Monika Zajkowska; Barbara Mroczko
Journal:  Cancers (Basel)       Date:  2020-05-28       Impact factor: 6.575

10.  Eosinophilic pleural effusion due to lung cancer has a better prognosis than non-eosinophilic malignant pleural effusion.

Authors:  Eiji Takeuchi; Yoshio Okano; Hisanori Machida; Katsuhiro Atagi; Yoshihiro Kondou; Naoki Kadota; Nobuo Hatakeyama; Keishi Naruse; Tsutomu Shinohara
Journal:  Cancer Immunol Immunother       Date:  2021-06-25       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.